PepCan
PepCan
Cancer & Peptide Vaccines
PepCan is indexed as peptide vaccine in the PeptideBase article library. It is referenced in “PepCan and HPV Peptide Vaccines: How to Read Early Cancer Vaccine Trials” and 2 other PeptideBase articles. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.
Deep Dives on PepCan
Start here for the plain-English articles connected to this peptide.
When a Peptide Cancer Study Is Retracted: What Retraction Does—and Does Not—Mean
What a peptide study retraction means, why ethics and provenance concerns can undermine confidence, and how readers can verify a paper's current status.
Read articleCan a KRAS Peptide Vaccine Prevent Pancreatic Cancer? What the First Human Trial Actually Shows
The first human mKRAS-VAX study generated mutant-KRAS-specific T-cell responses in 18 of 20 high-risk participants—but it did not prove pancreatic cancer prevention.
Read articlePepCan and HPV Peptide Vaccines: How to Read Early Cancer Vaccine Trials
The small PepCan trial did not prove that an HPV peptide vaccine prevents cancer recurrence. It shows why safety, immune signals, efficacy, statistical power, production problems, and conflicts must be read separately.
Read articleQuick Facts
- Origin
- Named peptide vaccine referenced in PeptideBase coverage
- Category
- Cancer & Peptide Vaccines